STOCKHOLM, Sweden, August 27, 2010. Karo Bio held a well attended seminar on Thursday. Professors Steven E. Nissen and Paul J. P. Kastelein together withDr Jens Kristensen, Karo Bio’s Chief Medical Officer, presented and discussed the rationale in the selected development route for eprotirome and the medical need for more effective treatments of dyslipidemia in high-risk patients with...

STOCKHOLM, Sweden, August 26, 2010. Karo Bio AB (publ) (Reuters: KARO. ST) today presents its development plan for the phase III studies of eprotirome as a novel pharmaceutical for the treatment of high-risk patients with heterozygous familial hypercholesterolemia (HeFH).

STOCKHOLM, August 11, 2010. The Swedish biotech company Karo Bio AB (publ) (Reuters: KARO. ST) today announced that the development plan for the upcoming phase III studies of eprotirome as a novel pharmaceutical for the treatment of high-risk patients with heterozygous familial hypercholesterolemia (HeFH) will be presented on Thursday August 26, 2010. In connection to the presentation, Professors...

STOCKHOLM, July 7, 2010. The Swedish biotech company Karo Bio AB (publ) (Reuters: KARO. ST) today announced the decision to initially develop its leading lipid-lowering candidate drug eprotirome for the treatment of high-risk patients with heterozygous familial hypercholesterolemia (HeFH).

STOCKHOLM, April 28, 2010. Karo Bio AB (publ) (Reuters: KARO. ST) today announced that the new President and CEO Fredrik Lindgren today has bought 500, 000 shares in the company.

At Karo Bio AB’s annual general meeting on Friday April 23, 2010, the following was resolved. DividendNo dividend is to be paid for the financial year 2009. Board of DirectorsMargaret von Platen, new electionBo Håkansson, re-electionJohan Kördel, re-electionJon Risfelt, re-electionBirgit Stattin Norinder, re-electionBo Håkansson was elected chairman of the board. Auditors PricewaterhouseCoopers...

STOCKHOLM, March 29, 2010. Karo Bio AB (publ) (Reuters: KARO. ST) today announced that the Karo Bio Board of Directors has appointed Fredrik Lindgren as new President and CEO. Fredrik Lindgren succeeds Per Olof Wallström who, as previously announced in a press release on February 16, has resigned and is leaving the company.

As of today, Karo Bio’s annual report for 2009 is available on the company’s web site, www. karobio. com >>> Click gere to read the annual report.

The annual general meeting of the shareholders of Karo Bio Aktiebolag (publ) will be held on Friday April 23, 2010 at 2.00 p. m. in Hörsalen, Mannheimer Swartling, Norrlandsgatan 21, Stockholm, Sweden.

LIPID LOWERING DRUG EPROTIROME Data demonstrate the potential for further reducing atherogenic lipids in statin-treated patients who do not reach their LDL-cholesterol goalsSTOCKHOLM, SWEDEN, March 10, 2010. The Swedish biotech company Karo Bio (Reuters: KARO. ST) today announced the publication of results from a clinical phase II trial evaluating the company’s liver selective thyroid hormone...

STOCKHOLM, February 16, 2010. Karo Bio AB (publ) (Reuters: KARO. ST) today announced that Per Olof Wallström, President and CEO of Karo Bio AB for the past five years, has decided to resign to pursue other opportunities. He intends to stay with the company until his successor has been appointed. "P. O. has been a dedicated and effective leader of our company", said Dr. Leon Rosenberg, Chair of...